Patent ID: 8026214

Claim:
A method for treating a Factor VII-responsive syndrome comprising administering to a subject in need thereof an effective amount of a liquid, aqueous, and pharmaceutically acceptable composition, the composition comprising (i) at least 0.01 mg/mL of a Factor VII polypeptide that exhibits substantially the same or improved biological activity as compared to wild type Factor VII; (ii) a buffering agent suitable for keeping pH of the composition in the range of about 4 to about 9; and (iii) a stabilizing composition comprising a benzamidine compound according to the formula —C 6 H 4 —C(═N—Z 1 —R 1 )—NH—Z 2 —R 2 , wherein (a) C 6 H 4 denotes a substituted benzene ring, and (b) Z 1 and Z 2 independently are selected from the group consisting of —O—, —S—, —NR H− and a single bond, where R H is selected from the group consisting of hydrogen, C 1-4 -alkyl, aryl and arylmethyl, and R 1 and R 2 independently are selected from the group consisting of hydrogen, optionally substituted C 1-6 -alkyl, optionally substituted C 2-6 -alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, wherein —C═N—Z 1 —R 1 optionally forms part of a heterocyclic ring, —C—NH—Z 2 —R 2 optionally forms part of a heterocyclic ring, or —C(═N—Z 1 —R 1 )—NH-Z 2 —R 2 optionally forms a heterocyclic ring wherein Z 1 —R 1 —R 2 —Z 2 — is a biradical.